Effect of rosiglitazone versus placebo on cardiovascular performance and myocardial triglyceride.

Trial Profile

Effect of rosiglitazone versus placebo on cardiovascular performance and myocardial triglyceride.

Completed
Phase of Trial: Phase IV

Latest Information Update: 03 Apr 2012

At a glance

  • Drugs Rosiglitazone (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Most Recent Events

    • 03 Apr 2012 Actual patient number changed from 111 to 150 as eported by ClinicalTrials.gov.
    • 03 Apr 2012 Company added in association field as reported by ClinicalTrials.gov.
    • 03 Apr 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top